Purple Biotech reports preclinical data for IM1240 cancer treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
April 27, 2026 7:00 AM EDTData, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment
New data shows that the NKG2A arm significantly enhanced anti-tumor activity in all samples and improved the therapeutic index
Immune cell structures known as a hallmark of effective anti-tumor immune response and favorable prognosis, were induced by IM1240 in a patient-derived non-small cell lung cancer (NSCLC) biopsy, corresponding with IM1240 anti-tumor efficacy Â
... More